Vimarsana
Biggest News Aggregation in the World

Page 8 - Silverstein Foundation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Silverstein Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Silverstein Foundation Today - Breaking & Trending Today

Investegate |Gain Therapeutics Announcements | Gain Therapeutics: Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors - Vimarsana News

Investegate |Gain Therapeutics Announcements | Gain Therapeutics: Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors

Gain Therapeutics Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. and Hans Peter Hasler as independent members to its Board of Directors. The new board additions will provide strategic guidance as the company focuses on identifying a...

Lilly Announces Agreement to Acquire Prevail Therapeutics - Vimarsana News

Lilly Announces Agreement to Acquire Prevail Therapeutics

Lilly Announces Agreement to Acquire Prevail Therapeutics Dec 24, 2020 12:07 PM ET Legal Newswire POWERED BY LAW.COM Eli Lilly and Company and Prevail Therapeutics Inc. announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of approximately $1.040 billion). The CVR i...

Source: law.com
GT Gain Therapeutics SA Announces Funding from the Swiss Innovation Agency Supporting a 3-year ... - Vimarsana News

GT Gain Therapeutics SA Announces Funding from the Swiss Innovation Agency Supporting a 3-year ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. GT Gain Therapeutics SA Announces Funding from the Swiss Innovation Agency Supporting a 3-year ... Gain TherapeuticsDecember 15, 2020 GMT - Researchers will further develop the Site-directed Enzyme Enhancement Therapy (SEE-Tx) ™ technology for the treatment of rare genetic and neurodegenerative diseases - The collaborative agreement unites resources from the Institute for Research in Biomedicine (IRB)-USI; Neurocentro - Ente Ospedaliero Cantonale (EOC) & GT GAIN Therapeutics, SA LUGANO, Switzerl...

Source: apnews.com
Lilly to acquire gene therapy specialist, Prevail Therapeutics, in a deal worth US$1.04bn - Vimarsana News

Lilly to acquire gene therapy specialist, Prevail Therapeutics, in a deal worth US$1.04bn

Lilly to acquire gene therapy specialist, Prevail Therapeutics, in a deal worth US$1.04bn US pharma giant, Eli Lilly and Co, announced today that it would buy Prevail Therapeutics Inc in a deal valued at US$1.04bn. The Indianapolis headquartered company said the acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease such as Parkinson’s disease or dementia. Lilly ...